Skip to content
Medical Health Aged Care

On this weekend – Brisbane Memory Walk & Jog

Dementia Australia 2 mins read

The 2024 Brisbane Memory Walk & Jog is upon us, with the much-anticipated event taking place this weekend on Sunday 26 May at Rocks Riverside Park, Seventeen Mile Rocks.

Starting at 7.30am, we welcome everyone in the Brisbane community to join fellow participants as they walk, jog or run to help raise money in support of people living with dementia.

 

Special guests, Dementia Australia Ambassador Wally Lewis AM will be in attendance alongside this year’s MC Dementia Australia Ambassador Takaya Honda.

 

Registrations for the Brisbane Memory Walk & Jog are still open and we would love to see as many people as possible participate to help raise funds and awareness for such an important cause.

 Walk or jog with us. We are in this together. 

 

Sign-up to walk, jog or run or join in as a Volunteer at a Memory Walk & Jog event at www.memorywalk.com.au. Share your Memory Walk & Jog experience on your socials and Donate today to support people living with dementia across Australia. 

 

Can’t attend this weekend? Organise your own group or individual walk or jog, with a My Way event. Choose your own date and location and register at www.memorywalk.com.au/get-involved/mw.

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.  

 

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au   

 

-Ends-

Media contacts: Ash Blakemore, Senior Media & Communications Advisor, 0448 170 672, ash.blakemore@dementia.org.au. Andrea Hogan, Media and Communications Manager, 0406 904 118, andrea.hogan@dementia.org.au

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.